ZA200301526B - Vaccine against streptococcus pneumoniae. - Google Patents
Vaccine against streptococcus pneumoniae. Download PDFInfo
- Publication number
- ZA200301526B ZA200301526B ZA200301526A ZA200301526A ZA200301526B ZA 200301526 B ZA200301526 B ZA 200301526B ZA 200301526 A ZA200301526 A ZA 200301526A ZA 200301526 A ZA200301526 A ZA 200301526A ZA 200301526 B ZA200301526 B ZA 200301526B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- immunogenic composition
- polysaccharide
- group
- phtd
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 26
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims description 20
- 229940031000 streptococcus pneumoniae Drugs 0.000 title claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 78
- 108090000623 proteins and genes Proteins 0.000 claims description 78
- 229920001282 polysaccharide Polymers 0.000 claims description 44
- 239000005017 polysaccharide Substances 0.000 claims description 44
- 150000004676 glycans Chemical class 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 22
- 239000002671 adjuvant Substances 0.000 claims description 16
- 230000002163 immunogen Effects 0.000 claims description 16
- 101100453077 Botryococcus braunii HDR gene Proteins 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 206010033078 Otitis media Diseases 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 102000014914 Carrier Proteins Human genes 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 159000000013 aluminium salts Chemical class 0.000 claims 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 101710188053 Protein D Proteins 0.000 claims 1
- 101710132893 Resolvase Proteins 0.000 claims 1
- 229960003983 diphtheria toxoid Drugs 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 229960001005 tuberculin Drugs 0.000 claims 1
- 230000027455 binding Effects 0.000 description 12
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 12
- 229960001231 choline Drugs 0.000 description 12
- 210000000987 immune system Anatomy 0.000 description 9
- 206010035664 Pneumonia Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 229920002704 polyhistidine Polymers 0.000 description 7
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 101710164918 Choline-binding protein Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 108091016312 choline binding proteins Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000035109 Pneumococcal Infections Diseases 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940124733 pneumococcal vaccine Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 208000031729 Bacteremia Diseases 0.000 description 2
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- -1 PRP polysaccharide Chemical class 0.000 description 2
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 2
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229940124858 Streptococcus pneumoniae vaccine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108700039582 histidine triad Proteins 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 208000022218 streptococcal pneumonia Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 description 1
- 101100420868 Anuroctonus phaiodactylus phtx gene Proteins 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101710183389 Pneumolysin Proteins 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101710151579 Zinc metalloproteinase Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001727 anti-capsular Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229940124731 meningococcal vaccine Drugs 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 229940031960 pneumococcal polysaccharide vaccine Drugs 0.000 description 1
- 229960001973 pneumococcal vaccines Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0022742.1A GB0022742D0 (en) | 2000-09-15 | 2000-09-15 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200301526B true ZA200301526B (en) | 2004-06-04 |
Family
ID=9899575
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200301524A ZA200301524B (en) | 2000-09-15 | 2003-02-25 | Vaccine. |
ZA200301526A ZA200301526B (en) | 2000-09-15 | 2003-02-25 | Vaccine against streptococcus pneumoniae. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200301524A ZA200301524B (en) | 2000-09-15 | 2003-02-25 | Vaccine. |
Country Status (25)
Country | Link |
---|---|
US (5) | US20040081662A1 (fr) |
EP (6) | EP1317279B1 (fr) |
JP (3) | JP4903975B2 (fr) |
KR (5) | KR100805991B1 (fr) |
CN (3) | CN100486642C (fr) |
AT (1) | ATE516815T1 (fr) |
AU (4) | AU2002238193B2 (fr) |
BR (2) | BR0113821A (fr) |
CA (2) | CA2421998C (fr) |
CY (1) | CY1111915T1 (fr) |
CZ (2) | CZ305324B6 (fr) |
DK (1) | DK1317279T3 (fr) |
ES (4) | ES2368902T3 (fr) |
GB (1) | GB0022742D0 (fr) |
HK (1) | HK1057698A1 (fr) |
HU (2) | HUP0301092A3 (fr) |
IL (4) | IL154608A0 (fr) |
MX (2) | MXPA03002265A (fr) |
NO (2) | NO336186B1 (fr) |
NZ (2) | NZ524287A (fr) |
PL (2) | PL210198B1 (fr) |
PT (1) | PT1317279E (fr) |
SI (1) | SI1317279T1 (fr) |
WO (2) | WO2002022167A2 (fr) |
ZA (2) | ZA200301524B (fr) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078042B2 (en) * | 1995-09-15 | 2006-07-18 | Uab Research Foundation | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
US7153952B1 (en) | 1997-07-02 | 2006-12-26 | sanofi pasteur limited/sanofi pasteur limitée | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
JP4846906B2 (ja) * | 1999-03-19 | 2011-12-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
US7074415B2 (en) * | 2000-06-20 | 2006-07-11 | Id Biomedical Corporation | Streptococcus antigens |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
EP1456231A2 (fr) | 2001-12-20 | 2004-09-15 | Shire Biochem Inc. | Antigenes de streptococcus |
EP2275122A3 (fr) * | 2002-04-02 | 2011-05-18 | Ben Gurion University Of The Negev Research And Development Authority | Vaccins contre le streptococcus pneumoniae à base de protéine |
US8691243B2 (en) | 2002-04-02 | 2014-04-08 | Ben-Gurion University Of The Negev Research And Development Authority | Protein-based Streptococcus pneumoniae vaccine |
JP4697706B2 (ja) | 2002-10-11 | 2011-06-08 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
US8229903B2 (en) * | 2002-12-19 | 2012-07-24 | International Business Machines Corporation | Suggesting data interpretations and patterns for updating policy documents |
EP2191844B1 (fr) * | 2003-01-30 | 2014-03-05 | Novartis AG | Vaccins injectables contre les multiples serogroupes du meningocoque |
PT1601689E (pt) | 2003-03-13 | 2008-01-04 | Glaxosmithkline Biolog Sa | Processo de purificação para citolisina bacteriana |
EP1477802A1 (fr) * | 2003-05-16 | 2004-11-17 | Erasmus Universiteit Rotterdam | Procédé de selection et de fabrication des constituents du vaccine, et leur utilisation en vaccines |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
CN103405761A (zh) | 2003-10-02 | 2013-11-27 | 诺华疫苗和诊断有限公司 | 多种脑膜炎球菌血清群的液体疫苗 |
CA2580693A1 (fr) * | 2004-09-21 | 2006-03-30 | Sanofi Pasteur, Inc. | Conjugues polysaccharide/proteine menogococciques multivalents derivatises et vaccin |
AU2011253684B8 (en) * | 2005-04-08 | 2013-07-11 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CN102716480B (zh) * | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
CN101378778B (zh) | 2005-12-22 | 2013-02-06 | 葛兰素史密丝克莱恩生物有限公司 | 肺炎球菌多糖缀合物疫苗 |
AU2006336520B2 (en) * | 2005-12-28 | 2011-09-15 | The Uab Research Foundation | Pneumococcal serotypes |
US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
EP2081953A2 (fr) * | 2006-08-17 | 2009-07-29 | The UAB Research Foundation | Polypeptides immunogeniques de pcpa e leur utilisations |
AR066676A1 (es) * | 2007-05-24 | 2009-09-02 | Glaxosmithkline Biolog Sa | Composicion antigenica liofilizada que contiene un agonista del receptor tipo toll |
AU2008267208B2 (en) | 2007-06-26 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
CN101802198B (zh) | 2007-07-23 | 2016-02-17 | 圣诺菲·帕斯图尔有限公司 | 免疫原性多肽和单克隆抗体 |
US20160228500A9 (en) * | 2007-07-23 | 2016-08-11 | Martina Ochs | Immunogenic Polypeptides and Monoclonal Antibodies |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
WO2009033742A2 (fr) * | 2007-09-14 | 2009-03-19 | Katholieke Universiteit Leuven | Vaccins contre le streptococcus pneumoniae |
US8404457B2 (en) * | 2008-02-01 | 2013-03-26 | Sanofi Pasteur Limited | Assay for diagnosing Streptococcus pneumoniae |
CA2716706C (fr) | 2008-03-03 | 2014-02-18 | Irm Llc | Composes et compositions servant de modulateurs de l'activite des tlr |
JP5668049B2 (ja) | 2009-03-24 | 2015-02-12 | ノバルティス アーゲー | 髄膜炎菌h因子結合タンパク質および肺炎球菌糖結合体の組み合わせ |
US9517263B2 (en) | 2009-06-10 | 2016-12-13 | Glaxosmithkline Biologicals Sa | Benzonaphthyridine-containing vaccines |
JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
BR112012004806B8 (pt) | 2009-09-02 | 2022-10-04 | Novartis Ag | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso |
SG178904A1 (en) | 2009-09-10 | 2012-04-27 | Novartis Ag | Combination vaccines against respiratory tract diseases |
CN101690810B (zh) * | 2009-10-21 | 2011-08-17 | 辽宁益康生物股份有限公司 | 一种鸡新城疫、传染性支气管炎、减蛋综合征、禽流感四联灭活疫苗佐剂及其制备方法 |
WO2011057148A1 (fr) | 2009-11-05 | 2011-05-12 | Irm Llc | Composés et compositions permettant de moduler l'activité des tlr-7 |
SG10201501980SA (en) | 2009-12-15 | 2015-05-28 | Novartis Ag | Homogeneous suspension of immunopotentiating compounds and uses thereof |
CN102939105B (zh) | 2009-12-22 | 2016-11-16 | 赛诺菲巴斯德有限公司 | 免疫原性组合物和相关的方法 |
US20130183350A1 (en) * | 2009-12-22 | 2013-07-18 | Kevin Harper | Immunogenic compositions |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
JP5848748B2 (ja) | 2010-03-23 | 2016-01-27 | アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc | 感染症、炎症、呼吸器疾患などの処置に使用するtlr2アゴニストとしての化合物(システインベースのリポペプチド)および組成物 |
WO2012072769A1 (fr) | 2010-12-01 | 2012-06-07 | Novartis Ag | Epitopes rrgb de pneumocoque et combinaisons de variantes |
JP6046632B2 (ja) * | 2010-12-03 | 2016-12-21 | サノフィ パストゥール リミテッドSanofi Pasteur Limited | 肺炎球菌に対する免疫用組成物 |
WO2012156391A1 (fr) * | 2011-05-17 | 2012-11-22 | Glaxosmithkline Biologicals S.A. | Vaccin contre le streptococcus pneumoniae |
JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Streptococcuspneumoniae抗原の増強された製剤 |
JP2014000016A (ja) * | 2012-06-15 | 2014-01-09 | National Agriculture & Food Research Organization | 豚丹毒菌の新規な抗原タンパク質、その遺伝子、及び組換えベクターとその利用 |
RU2510281C2 (ru) * | 2012-06-22 | 2014-03-27 | Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп") | ВАКЦИНА ПРОТИВ ПНЕВМОНИИ, ВЫЗЫВАЕМОЙ Streptococcus pneumoniae, НА ОСНОВЕ ГИБРИДНОГО БЕЛКА |
KR20150058571A (ko) * | 2012-10-17 | 2015-05-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
GB201218660D0 (en) | 2012-10-17 | 2012-11-28 | Glaxosmithkline Biolog Sa | Immunogenic composition |
ES2642967T3 (es) | 2013-01-01 | 2017-11-20 | Agfa Graphics Nv | Copolímeros (de etileno, vinilacetal) y precursores de plancha de impresión litográfica que incluyen tales copolímeros |
CA2899787A1 (fr) | 2013-02-01 | 2014-08-07 | Glaxosmithkline Biologicals Sa | Administration intradermique de compositions immunologiques comprenant des agonistes des recepteurs de type toll |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2015183676A1 (fr) * | 2014-05-29 | 2015-12-03 | Kapre Subhash V | Peptides synthétiques en tant que supports pour la conjugaison avec des polysaccharides |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
BR112018068753A2 (pt) | 2016-03-16 | 2019-01-22 | Agfa Nv | método para processar uma chapa de impressão litográfica |
US11844829B2 (en) | 2016-12-28 | 2023-12-19 | Zalvac Ab | Microparticles from Streptococcus pneumoniae as vaccine antigens |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
KR102634811B1 (ko) | 2017-06-10 | 2024-02-06 | 인벤트프라이즈 인크. | 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
MX2020008417A (es) | 2018-02-12 | 2020-11-11 | Inimmune Corp | Ligandos de receptores de tipo toll. |
CA3133185A1 (fr) * | 2019-03-13 | 2020-09-17 | St. Jude Children's Research Hospital | Compositions vaccinales et methodes de reduction de la transmission de streptococcus pneumoniae |
EP3778253A1 (fr) | 2019-08-13 | 2021-02-17 | Agfa Nv | Procédé de fabrication d'une plaque d'impression lithographique |
WO2022096590A1 (fr) | 2020-11-04 | 2022-05-12 | Eligo Bioscience | Particules dérivées de phages pour l'administration in situ de charge utile d'adn dans une population de c. acnes |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
BE889979A (fr) | 1981-08-14 | 1982-02-15 | Smith Kline Rit | Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation |
US5360897A (en) * | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
US4761283A (en) * | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US4882317A (en) * | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5006914A (en) * | 1988-12-02 | 1991-04-09 | Advanced Technology Materials, Inc. | Single crystal semiconductor substrate articles and semiconductor devices comprising same |
WO1990006951A1 (fr) * | 1988-12-16 | 1990-06-28 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Mutants de pneumolysine et vaccins contre le pneumocoque obtenus a partir de tels mutants |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
CA2059693C (fr) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Antigenes polysaccharides de streptococcus pneumoniae |
CA2059692C (fr) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Vaccin conjugue de polysaccharide contre les pneumocoques |
WO1992014488A1 (fr) | 1991-02-15 | 1992-09-03 | Uab Research Foundation | Gene de structure de proteine de pneumocoque |
US5980909A (en) * | 1991-02-15 | 1999-11-09 | Uab Research Foundation | Epitopic regions of pneumococcal surface protein A |
US6592876B1 (en) | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
US5476929A (en) | 1991-02-15 | 1995-12-19 | Uab Research Foundation | Structural gene of pneumococcal protein |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
US5371197A (en) * | 1991-09-24 | 1994-12-06 | Merck & Co., Inc. | Protein-dimeric polysaccharide conjugate vaccine |
DK0652758T3 (da) | 1992-06-18 | 2000-05-08 | Harvard College | Diferitoxin-vacciner |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
WO1994006465A1 (fr) * | 1992-09-16 | 1994-03-31 | The University Of Tennessee Research Corporation | Antigene de la proteine m hybride et porteur destine au vaccin anti-streptococcique du groupe a |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
GB9224584D0 (en) | 1992-11-23 | 1993-01-13 | Connaught Lab | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
EP0812593B8 (fr) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Compositions vaccinales renfermant de lipide A monophosphorylique 3-0-desacétylé |
EP0699076B1 (fr) | 1993-05-18 | 2002-10-30 | The Ohio State University Research Foundation | Vaccin contre l'otite moyenne |
ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
WO1995024176A1 (fr) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Dispositif de remplissage d'ampoule |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
EP1167379A3 (fr) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Oligonucléotides immunomodulateurs |
US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
HUP0600442A3 (en) | 1995-06-07 | 2007-03-28 | Biochem Vaccines Inc | Streptococcal heat shock proteins members of the hsp70 family |
GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
JP2000511411A (ja) * | 1996-05-01 | 2000-09-05 | ザ ロックフェラー ユニヴァーシティ | 抗―肺炎球菌ワクチン用のコリン結合タンパク質 |
US6245335B1 (en) * | 1996-05-01 | 2001-06-12 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
US5744417A (en) | 1996-05-02 | 1998-04-28 | Lyondell Petrochemical Company | Supported catalyst |
US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
ATE234129T1 (de) | 1996-06-18 | 2003-03-15 | Alza Corp | Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten |
EP0956289A4 (fr) | 1996-08-16 | 2004-10-13 | Smithkline Beecham Corp | Nouveaux polynucleotides et polypeptides procaryotes et leurs utilisations |
US5882896A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
US5882871A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | Saliva binding protein |
WO1998018931A2 (fr) | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Polynucleotides et sequences de streptococcus pneumoniae |
EP0942984A2 (fr) | 1996-11-12 | 1999-09-22 | Regents Of The University Of Minnesota | Proteine de liaison c3 de streptococcus pneumoniae |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
ATE234649T1 (de) | 1996-12-20 | 2003-04-15 | Alza Corp | Vorrichtung und verfahren zur erhöhung des transdermalen wirkstoffeflusses |
DE19708537A1 (de) | 1997-03-03 | 1998-09-10 | Biotechnolog Forschung Gmbh | Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc. |
FR2763244B1 (fr) * | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
CA2292838A1 (fr) | 1997-06-03 | 1998-12-10 | Connaught Laboratories Limited | Genes du recepteur de la lactoferrine de moraxella |
JP2001510031A (ja) | 1997-07-21 | 2001-07-31 | ノース・アメリカン・ヴァクシン・インコーポレーテッド | ワクチンとしての修飾された免疫原ニューモリシン組成物 |
US6224880B1 (en) * | 1997-09-24 | 2001-05-01 | Merck & Co., Inc. | Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines |
BR9812525A (pt) * | 1997-09-24 | 2000-07-25 | Univ Minnesota | Proteinase degradadora de complemento humano c3 de streptococcus pneumoniae |
EP0916726A1 (fr) * | 1997-11-13 | 1999-05-19 | Rijksuniversiteit te Groningen | Substances à propriété de fixation sur des microorganismes |
WO1999027961A1 (fr) | 1997-12-02 | 1999-06-10 | Powderject Vaccines, Inc. | Administration transdermique de compositions particulaires de vaccins |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
US6709658B1 (en) * | 1998-02-12 | 2004-03-23 | Wyeth Holdings Corporation | Pneumococcal vaccines formulated with interleukin-12 |
CN1191851C (zh) | 1998-04-07 | 2005-03-09 | 圣朱德儿童研究医院 | 包含胆碱结合蛋白an-末端截取物的氨基酸的多肽、由该多肽衍生的疫苗及其应用 |
ATE461709T1 (de) | 1998-04-07 | 2010-04-15 | Medimmune Llc | Choline-bindende proteine derivate aus pneumokoken als impfstoff |
WO1999053940A1 (fr) | 1998-04-23 | 1999-10-28 | Uab Research Foundation | Proteine de surface pneumococcique c(pspc), regions epitopes et selection de souches d'une telle proteine, et utilisations correspondantes |
GB9812613D0 (en) | 1998-06-11 | 1998-08-12 | Smithkline Beecham Biolog | Vaccine |
IL142017A0 (en) | 1998-09-24 | 2002-03-10 | Univ Minnesota | Human complement c3-degrading polypeptide from streptococcus pneumoniae |
WO2000030299A1 (fr) | 1998-11-17 | 2000-05-25 | Schlumberger Technology Corporation | Transmission de donnees dans une liaison de communications |
WO2000029434A2 (fr) | 1998-11-19 | 2000-05-25 | St. Jude Children's Research Hospital | IDENTIFICATION ET CARACTERISATION DE NOUVELLES PROTEINES PNEUMOCOCCIQUES SE LIANT A LA CHOLINE, CbpG AND CbpD, ET UTILISATIONS DIAGNOSTIQUES ET THERAPEUTIQUES CORRESPONDANTES |
EP2050464B1 (fr) * | 1998-12-21 | 2019-08-07 | Medimmune, Inc. | Protéines de streptococcus pneumoniae et fragments immunogènes pour vaccins |
EP1034792A1 (fr) * | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Administration par voie intranasale de vaccins à base de polyosides de Pneumococcus |
JP4846906B2 (ja) * | 1999-03-19 | 2011-12-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
CA2379327A1 (fr) * | 1999-06-10 | 2000-12-21 | Uab Research Foundation | Vaccin a combinaison de proteines de surface pneumococciques |
ATE325620T1 (de) | 1999-06-10 | 2006-06-15 | Medimmune Inc | Streptococcus pneumoniae proteine und impfstoffe |
US6319224B1 (en) | 1999-08-20 | 2001-11-20 | Bioject Medical Technologies Inc. | Intradermal injection system for injecting DNA-based injectables into humans |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
-
2000
- 2000-09-15 GB GBGB0022742.1A patent/GB0022742D0/en not_active Ceased
-
2001
- 2001-09-12 HU HU0301092A patent/HUP0301092A3/hu unknown
- 2001-09-12 EP EP01984626A patent/EP1317279B1/fr not_active Revoked
- 2001-09-12 KR KR1020037003731A patent/KR100805991B1/ko not_active IP Right Cessation
- 2001-09-12 HU HU0301043A patent/HUP0301043A3/hu not_active Application Discontinuation
- 2001-09-12 CZ CZ2003-756A patent/CZ305324B6/cs not_active IP Right Cessation
- 2001-09-12 CN CNB018157467A patent/CN100486642C/zh not_active Expired - Fee Related
- 2001-09-12 EP EP10179133A patent/EP2305297A1/fr not_active Ceased
- 2001-09-12 ES ES01984626T patent/ES2368902T3/es not_active Expired - Lifetime
- 2001-09-12 KR KR1020107014638A patent/KR20100091241A/ko not_active Application Discontinuation
- 2001-09-12 CN CNB018157483A patent/CN1253205C/zh not_active Expired - Fee Related
- 2001-09-12 SI SI200131001T patent/SI1317279T1/sl unknown
- 2001-09-12 EP EP01984627.8A patent/EP1317280B1/fr not_active Expired - Lifetime
- 2001-09-12 US US10/380,563 patent/US20040081662A1/en not_active Abandoned
- 2001-09-12 EP EP10178332.2A patent/EP2314313B1/fr not_active Expired - Lifetime
- 2001-09-12 MX MXPA03002265A patent/MXPA03002265A/es active IP Right Grant
- 2001-09-12 NZ NZ524287A patent/NZ524287A/en not_active IP Right Cessation
- 2001-09-12 KR KR1020117026231A patent/KR101268790B1/ko not_active IP Right Cessation
- 2001-09-12 JP JP2002526416A patent/JP4903975B2/ja not_active Expired - Fee Related
- 2001-09-12 EP EP10179135A patent/EP2305298A1/fr not_active Withdrawn
- 2001-09-12 IL IL15460801A patent/IL154608A0/xx unknown
- 2001-09-12 KR KR1020087020661A patent/KR100991916B1/ko not_active IP Right Cessation
- 2001-09-12 AU AU2002238193A patent/AU2002238193B2/en not_active Ceased
- 2001-09-12 US US10/380,575 patent/US20060051361A1/en not_active Abandoned
- 2001-09-12 PL PL361401A patent/PL210198B1/pl unknown
- 2001-09-12 NZ NZ524286A patent/NZ524286A/en not_active IP Right Cessation
- 2001-09-12 AU AU3819302A patent/AU3819302A/xx active Pending
- 2001-09-12 AT AT01984626T patent/ATE516815T1/de active
- 2001-09-12 ES ES01984627.8T patent/ES2545876T3/es not_active Expired - Lifetime
- 2001-09-12 BR BR0113821-9A patent/BR0113821A/pt active Pending
- 2001-09-12 IL IL15460701A patent/IL154607A0/xx unknown
- 2001-09-12 BR BR0113822-7A patent/BR0113822A/pt not_active IP Right Cessation
- 2001-09-12 KR KR10-2003-7003732A patent/KR20030031188A/ko not_active Application Discontinuation
- 2001-09-12 WO PCT/EP2001/010568 patent/WO2002022167A2/fr active Search and Examination
- 2001-09-12 CN CN2009101285337A patent/CN101502648B/zh not_active Expired - Fee Related
- 2001-09-12 PL PL361395A patent/PL209247B1/pl unknown
- 2001-09-12 AU AU2054802A patent/AU2054802A/xx active Pending
- 2001-09-12 CZ CZ2003-757A patent/CZ305343B6/cs not_active IP Right Cessation
- 2001-09-12 JP JP2002526417A patent/JP4880184B2/ja not_active Expired - Fee Related
- 2001-09-12 ES ES10178332.2T patent/ES2659400T3/es not_active Expired - Lifetime
- 2001-09-12 CA CA2421998A patent/CA2421998C/fr not_active Expired - Fee Related
- 2001-09-12 ES ES09173889.8T patent/ES2551097T3/es not_active Expired - Lifetime
- 2001-09-12 PT PT01984626T patent/PT1317279E/pt unknown
- 2001-09-12 WO PCT/EP2001/010570 patent/WO2002022168A2/fr active Application Filing
- 2001-09-12 MX MXPA03002264A patent/MXPA03002264A/es active IP Right Grant
- 2001-09-12 AU AU2002220548A patent/AU2002220548B2/en not_active Ceased
- 2001-09-12 EP EP09173889.8A patent/EP2140878B1/fr not_active Expired - Lifetime
- 2001-09-12 CA CA2422002A patent/CA2422002C/fr not_active Expired - Fee Related
- 2001-09-12 DK DK01984626.0T patent/DK1317279T3/da active
-
2003
- 2003-02-24 IL IL154607A patent/IL154607A/en not_active IP Right Cessation
- 2003-02-24 IL IL154608A patent/IL154608A/en not_active IP Right Cessation
- 2003-02-25 ZA ZA200301524A patent/ZA200301524B/en unknown
- 2003-02-25 ZA ZA200301526A patent/ZA200301526B/en unknown
- 2003-03-14 NO NO20031183A patent/NO336186B1/no not_active IP Right Cessation
- 2003-03-14 NO NO20031184A patent/NO337730B1/no not_active IP Right Cessation
- 2003-11-19 HK HK03108447.9A patent/HK1057698A1/xx not_active IP Right Cessation
-
2007
- 2007-05-07 US US11/745,006 patent/US20080081050A1/en not_active Abandoned
-
2010
- 2010-08-13 US US12/855,734 patent/US20110008419A1/en not_active Abandoned
-
2011
- 2011-09-12 JP JP2011198277A patent/JP2012006969A/ja active Pending
- 2011-10-06 CY CY20111100958T patent/CY1111915T1/el unknown
-
2013
- 2013-12-10 US US14/101,995 patent/US20140099339A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200301526B (en) | Vaccine against streptococcus pneumoniae. | |
KR101418240B1 (ko) | 백신 | |
US8926985B2 (en) | Vaccine | |
AU2002220548A1 (en) | Vaccine against streptococcus penumoniae | |
EP2908856B1 (fr) | Composition immunogène | |
JP2013521315A (ja) | 担体タンパク質にコンジュゲートされた肺炎連鎖球菌多糖類を含んでなる免疫原性組成物 | |
KR20140145941A (ko) | 컨쥬게이션 방법 | |
US20140105927A1 (en) | Immunogenic composition | |
US20140193451A1 (en) | Immunogenic composition | |
Paton | New pneumococcal vaccines: basic science developments |